New 'Living Drug' trial offers hope for tough blood cancers
NCT ID NCT07239323
Summary
This early-stage study is testing a new type of CAR-T cell therapy for adults with advanced blood cancers that have come back or not responded to other treatments. Doctors will give patients a one-time infusion of specially engineered immune cells designed to attack cancer. The main goals are to find a safe dose and see if the treatment can help control the disease, with patients being followed for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
RECRUITINGKunming, Yunnan, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.